Skip to Main Content
Phase III

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Study HIC#:2000034017
  • Last Updated:05/31/2024

This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    Trial Purpose and Description

    To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.

    Eligibility Criteria

    Inclusion Criteria:

    • For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled

      • For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
      • In addition, laboratory reports detailing evidence of BCR-ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
    • >= 1 year (365 days) and =< 21 years at ALL diagnosis
    • Ph+ (BCR-ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR-ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies
    • ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization (FISH, e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based ribonucleic acid (RNA)-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, CA, USA or similar)
    • Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy
    • Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine
    • Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib
    • ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)
    • ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose
    • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
    • Direct bilirubin =< 2.0 mg/dL
    • Shortening fraction of >= 27% by echocardiogram
    • Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
    • Corrected QT interval, QTc < 480 msec

      • Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
    • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:

      • 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
      • 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
      • 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
      • 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
      • 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
      • >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)

    Exclusion Criteria:

    • Known history of chronic myelogenous leukemia (CML)
    • ALL developing after a previous cancer treated with cytotoxic chemotherapy
    • Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
    • Down syndrome
    • Pregnancy and breast feeding

      • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential
      • Lactating females who plan to breastfeed their infants
      • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
    • Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block
    • Prior treatment with dasatinib, or any TKI other than imatinib